|
|
2010
| IRX Therapeutics raises $8 million to develop therapeutic
vaccines for cancer and viral diseases. |
Elected George P. Denny III and John D. Halpern, Founders of Halpern, Denny & Co., to Board of Directors.
IRX Therapeutics announces cancer vaccine collaboration with Japan's National Cancer Research Center. |
| IRX Therapeutics appoints Neil L. Berinstein, MD Chief Scientific Officer. |
2008
IRX Therapeutics completes $25 million Series A preferred stock offering
IRX Therapeutics presents Phase 2 results at 3rd European Conference on Head & Neck Oncology. |
IRX Therapeutics presents at the 26th Annual JP Morgan H&Q
Conference.
Active planning for the global Phase 3 trial of IRX-2 is underway. |
2007
| IRX Therapeutics completes enrollment of their Phase 2 U.S. Clinical Trial. |
| Declan P. Doogan, M.D. joins IRX Therapeutics as Advisor on Global Product Development. |
| IRX Therapeutics completes second $12.5 million convertible note offering. |
IRX Therapeutics presents at the 25th annual JP Morgan H&Q Conference.
John W. Hadden II named President & Chief Executive Officer |
2006
Jean Louis-Lefebvre, M.D. joins IRX Therapeutics' Medical
Advisory Board. |
| Elected Frank J. Loverro, Managing Director of Kelso Company, to Board of Directors. |
|
